Evidence map›Paper›PMID 29658007›Full record

ReviewClinical and translational radiation oncology2017

Organ preservation in rectal cancer - Challenges and future strategies.

C Gani, P Bonomo, K Zwirner, C Schroeder, A Menegakis, C Rödel, D Zips

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Clinical and translational radiation oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03561142 (Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy. A Prospective Phase II Pilot Trial of the German Rectal Cancer Study Group), which is not on this map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03561142 phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy. A Prospective Phase II Pilot Trial of the German Rectal Cancer Study Group

TypeinterventionalSponsorUniversity Hospital TuebingenRan2018 to 2024Enrolled94ConditionsRectal Cancer, Rectal Neoplasms, Rectal Cancer Stage II, Rectal Cancer Stage IIIArmsRadiotherapy, Chemotherapy, Deep regional hyperthermia
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Crying Need for a Better Response Assessment in Rectal Cancer.Current treatment options in oncology · 2023
    Review
  5. Article
  6. Multimodal Treatment of Rectal Cancer.Deutsches Arzteblatt international · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. In favor of total neoadjuvant therapy (TNT) for locally advanced rectal carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Article
  14. Heating technology for malignant tumors: a review.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2020
    Review
  15. Article
  16. Online MR guided radiotherapy for rectal cancer. New opportunities.Clinical and translational radiation oncology · 2019
    Review
  17. Review
  18. Article
  19. [Evidence-based surgery of rectal cancer].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2019
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

C GaniDepartment of Radiation Oncology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
P BonomoDepartment of Radiation Oncology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
K ZwirnerDepartment of Radiation Oncology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
C SchroederInstitute of Medical Genetics and Applied Genomics, Medical Faculty and University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
A MenegakisDepartment of Radiation Oncology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
C RödelDepartment of Radiotherapy and Oncology, University of Frankfurt, Frankfurt am Main, Germany.
D ZipsDepartment of Radiation Oncology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
University Children's Hospital Tübingen · DEUniversity of Tübingen · DEAzienda Ospedaliero-Universitaria Careggi · ITFrankfurt Cancer Institute · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoadjuvant radiochemotherapy with subsequent total mesorectal excision is the standard of care for locally advanced rectal cancer. While this multimodal strategy has decreased local recurrences rates below 5%, long-term morbidities are considerable in terms of urinary, sexual or bowel functioning. At the same time approximately 10-20% of patients have no evidence of residual tumour in their surgical specimen. Pioneering studies from Brazil have suggested that surgery can safely be omitted in carefully selected patients with a clinical complete response after radiochemotherapy. Although confirmatory studies showed similar results, challenges in terms of optimizing radiochemotherapy for organ-preservation, appropriate selection of patients for non-operative management and the safety of this approach remain. The present review will summarize the current data on organ-preservation in rectal cancer and discuss the challenges that need to be addressed in future trials.

Indexed as

ChemoradiotherapyOrgan preservationRadiochemotherapyRadiotherapyRectal cancerWait and see

Identifiers

PMID29658007
PMCPMC5893528
OpenAlexW2600487384

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.